Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome

American Journal of Gastroenterology

Volumn 107, Issue 9, 2012, Pages 1426-1440

  Drossman, Douglas A ^a   Morris, Carolyn B ^a   Edwards, Hollie ^a   Wrennall, Christina E D ^a   Weinland, Stephan R ^a   Aderoju, Ademola O ^a   Kulkarni Kelapure, Renuka R ^a   Hu, Yuming J ^a   Dalton, Christine ^a   Bouma, Megan H ^a   Zimmerman, Joseph ^a,b   Rooker, Ceciel ^a   Leserman, Jane ^a   Bangdiwala, Shrikant I ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE SULFATE; NARCOTIC AGENT; OXYCODONE; PETHIDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CATASTROPHIZING; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DRUG DETOXIFICATION; DRUG DOSE ESCALATION; ENTEROPATHY; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HOSPITALIZATION; HUMAN; MALE; NARCOTIC BOWEL SYNDROME; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECIDIVISM; SHORT FORM 36; TREATMENT OUTCOME; TREATMENT RESPONSE; UNEMPLOYMENT; VISUAL ANALOG SCALE;

ABDOMINAL PAIN; ADULT; ANALGESICS, OPIOID; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; SUBSTANCE-RELATED DISORDERS; SYNDROME; TREATMENT OUTCOME;

EID: 84866073835     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.142     Document Type: Article

References (23)

1. Grunkemeier DMS, Cassara JE, Dalton CB et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007;5:1126-39.
2. Sandgren JE, Mc Phee MS, Greenberger NJ. Narcotic bowel syndrome treated with Clonidine. Ann Intern Med 1984; 101: 331-4.
3. Rogers M, Cerda JJ. Editorial: the narcotic bowel syndrome. J Clin Gastroenterol 1989;11:132-5.
4. Tuteja AK, Biskupiak J, Stoddard GJ et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010;22:424-e96.
5. Drossman DA, Li Z, Toner BB et al. Functional bowel disorders: a mul-ticenter comparison of health status, and development of illness severity index. Dig Dis Sci 1995;40:986-95.
6. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-99.
7. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987; 30: 191-7.
8. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4.
9. Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain 1983;17:33-44.
10. Drossman D, Morris CB, Hu Y et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007;102:1442-53.
11. Patrick DL, Drossman DA, Frederick IO et al. Quality of lifeinpersons with irritable bowel syndrome: development of a new measure. Dig Dis Sci 1998;43:400-11.
12. Ware JE, Sherbourne CD. The MOS 36-item short form Health Survey (SF-36): 1. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
13. Derogatis LR. SCL-90-R: Administration, Scoring, and Procedures Manual II-For the R(evised) Version. Clinical Psychometric Research: Towson, MD 1983.
14. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70.
15. Drossman DA, Leserman J, Nachman G et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990;113:828-33.
16. Butler SF, Budman SH, Fernandez KC et al. Development and validation of the Current Opioid Misuse Measure. Pain 2007;130:144-56.
17. Trescot AM, Boswell MV, Atluri SL et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-39.
18. Ackerman SJ, Mordin M, Reblando J et al. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm 2003;9:223-31.
19. Hutchinson MR, Bland ST, Johnson KW et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Scientific World Journal 2007;7:98-111.
20. Agostini S, Eutamene H, Cartier C et al. Evidence of central and peripheral sensitization in a rat model of narcotic bowel-like syndrome. Gastroenterol 2010; 139: 553-63.
21. Grover M, Drossman DA. Psychopharmacologic & behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am 2009;19:151-70.
22. Grover M, Dorn SD, Weinland SR et al. Atypical antipsychotic Quetiapine in the management of severe, refractory functional gastrointestinal disorders. Dig Dis Sci 2009;54:1284-91.
23. Drossman DA. Beyond tricyclics: new ideas for treating patients with painful and refractory functional GI symptoms. Am J Gastroenterol 2009;104:2897-902.